McKesson (MCK) earnings call transcripts

Management framed the quarter as broad-based momentum supporting a modestly higher full-year outlook, while flagging timing effects and second-half investments.

Management framed fiscal 2027 as continued operating momentum despite pricing headwinds, acquisition laps, cash-flow normalization and portfolio separation execution.

Management framed the quarter as broad-based execution, raising FY26 EPS while stressing specialty growth, automation, and resilient manufacturer economics.

Management framed performance as broad-based execution, with growth platforms outperforming while planned investments and portfolio discipline shape the back half.

Management framed fiscal 2026 around sustained pharmaceutical momentum, disciplined portfolio reshaping, and resilient execution despite policy uncertainty.

Management portrayed durable pharmaceutical and oncology momentum offset by an unusually soft illness season and cautious Medical-Surgical outlook.

Management framed the quarter as broad-based execution, with confidence in core distribution and strategic platforms despite Medical and RxTS variability.

Mixed segment trends left strategy intact: US Pharma and oncology led, while Med-Surg and RxTS encountered specific execution headwinds.

Management framed FY25 around durable core growth, Optum expansion, and continued investment in oncology and technology-enabled services.

Management framed the quarter as broad-based execution, with GLP-1 moderation and Rite Aid largely contained but capital returns reduced.